The importance of the health care payer view in the development of a new compund is exemplarily shown and was presented at a conference in London in March 2012
Digital Pharma: Evolution and Revolution in Marketing & SalesLen Starnes
A review for non-pharma audiences of evolutionary and revolutionary changes in pharma marketing and sales since the mid 90s. Presented at ENG's Effective Web Marketing and Search Engine Marketing conference, Brussels, November, 2007.
Pharma Marketing Digital Trends to Watch in 2020. A closer look at some of the future directions that Pharma Marketing need in 2020 to arm themselves for in full readiness for the next 12 Months
The document outlines a methodological framework for estimating the size of pharmaceutical markets at the global, regional, national and local levels. It discusses defining the products, level of analysis, time periods and data sources used to estimate market turnover, consumption and production within wholesale and retail pharmaceutical markets. As an example, it also provides data on estimated 2009 market sizes for various Central and Southeast European countries.
Opportunities & Challenges in West Africa's (Ghana & Nigeria) Healthcare and ...Aiswariya Chidambaram
This presentation made at the Pharma Insights Briefing session of CPhI Worldwide 2014, Paris, provides information on the market opportunities of
the fastest growing pharmaceutical markets in Africa: Ghana and Nigeria.
• Market sizing and Growth Trends
• Key Merger, Acquisition and Partnership Assessment
• Market Drivers and Challenges
• Pharmaceutical Procurement, Supply, Distribution and Retail
• SWOT and PESTLE Analysis
• Competitive Landscape Analysis
• Therapeutic Area Growth Analysis
• Strategic Recommendations
The document discusses healthcare in India and the use of telemedicine. It provides an overview of the size and structure of the healthcare industry in India. It then discusses hospital service marketing and the key elements of the marketing mix for hospitals. The document introduces Apollo Hospitals and its telemedicine network, which uses technologies like video conferencing to provide remote access to medical experts and services.
Pre-Launch Planning: Priming Your Pharma Brand For Profit And Success (mini)Eularis
In today’s environment, Pharmaceutical companies find themselves in a bind. Until recently, if drugs made over $500 Million in annual revenue within 3 to 5 years of launch, they were considered hugely successful. They were a support to an extensive company portfolio and a component of greater company profit.
However, things have changed. The standards for a successful drug have become much higher and much more dangerous. With so many revenue-producing drugs going off patent, companies are facing large holes in their balance sheets and sales that are increasingly slow.
Plus, with the stakes high and available funds low, pipelines are drying up. Add to this the closer scrutiny of safety issues, the rise of Generics, slower physician acceptance and adoption of new therapies, and the Pharma Industry is in trouble.
More and more, companies are expecting marketers to be instrumental at the key moment of launch, and marketers are under extreme pressure. To deliver on the high hopes of Pharmaceutical brand launch, companies must engage in comprehensive pre-launch planning.
In this report we analyze why launch is increasingly important, the issues involved in pre-launch planning, including key organizational strategies, marketing tactics, regulatory considerations, global issues, and methods for ensuring the most effective plans.
Successful market / customer access is a primary objective in healthcare marketing. This presentation provides the insight to successfully position, price and promote your pharmaceutical, medical device or clinical service in leading healthcare market segments.
This presentation is from www.healthcaremedicalpharmaceuticaldirectory.com, no subscription is required. Please visit us to see more presentations about the latest marketing trends in the healthcare industry.
John Baresky Healthcare Marketing Leader, Pharmaceutical Marketing, Digital Marketing Strategy, Content Marketing Strategy, Market Access Strategy, Healthcare RPA Software Marketing Strategy
www.healthcaremedicalpharmaceuticaldirectory.com
John G. Baresky
https://www.linkedin.com/in/johngbaresky
#baresky
This document discusses factors related to switching medications from prescription to over-the-counter status. It begins by defining Rx-to-OTC switching as transferring FDA-approved prescription medications to non-prescription, over-the-counter status. The document then covers stakeholders impacted by switching, the switching process and principles, factors contributing to successful switches, considerations for switches, and strategies for building brand equity during and after a switch from prescription to over-the-counter status.
Digital Pharma: Evolution and Revolution in Marketing & SalesLen Starnes
A review for non-pharma audiences of evolutionary and revolutionary changes in pharma marketing and sales since the mid 90s. Presented at ENG's Effective Web Marketing and Search Engine Marketing conference, Brussels, November, 2007.
Pharma Marketing Digital Trends to Watch in 2020. A closer look at some of the future directions that Pharma Marketing need in 2020 to arm themselves for in full readiness for the next 12 Months
The document outlines a methodological framework for estimating the size of pharmaceutical markets at the global, regional, national and local levels. It discusses defining the products, level of analysis, time periods and data sources used to estimate market turnover, consumption and production within wholesale and retail pharmaceutical markets. As an example, it also provides data on estimated 2009 market sizes for various Central and Southeast European countries.
Opportunities & Challenges in West Africa's (Ghana & Nigeria) Healthcare and ...Aiswariya Chidambaram
This presentation made at the Pharma Insights Briefing session of CPhI Worldwide 2014, Paris, provides information on the market opportunities of
the fastest growing pharmaceutical markets in Africa: Ghana and Nigeria.
• Market sizing and Growth Trends
• Key Merger, Acquisition and Partnership Assessment
• Market Drivers and Challenges
• Pharmaceutical Procurement, Supply, Distribution and Retail
• SWOT and PESTLE Analysis
• Competitive Landscape Analysis
• Therapeutic Area Growth Analysis
• Strategic Recommendations
The document discusses healthcare in India and the use of telemedicine. It provides an overview of the size and structure of the healthcare industry in India. It then discusses hospital service marketing and the key elements of the marketing mix for hospitals. The document introduces Apollo Hospitals and its telemedicine network, which uses technologies like video conferencing to provide remote access to medical experts and services.
Pre-Launch Planning: Priming Your Pharma Brand For Profit And Success (mini)Eularis
In today’s environment, Pharmaceutical companies find themselves in a bind. Until recently, if drugs made over $500 Million in annual revenue within 3 to 5 years of launch, they were considered hugely successful. They were a support to an extensive company portfolio and a component of greater company profit.
However, things have changed. The standards for a successful drug have become much higher and much more dangerous. With so many revenue-producing drugs going off patent, companies are facing large holes in their balance sheets and sales that are increasingly slow.
Plus, with the stakes high and available funds low, pipelines are drying up. Add to this the closer scrutiny of safety issues, the rise of Generics, slower physician acceptance and adoption of new therapies, and the Pharma Industry is in trouble.
More and more, companies are expecting marketers to be instrumental at the key moment of launch, and marketers are under extreme pressure. To deliver on the high hopes of Pharmaceutical brand launch, companies must engage in comprehensive pre-launch planning.
In this report we analyze why launch is increasingly important, the issues involved in pre-launch planning, including key organizational strategies, marketing tactics, regulatory considerations, global issues, and methods for ensuring the most effective plans.
Successful market / customer access is a primary objective in healthcare marketing. This presentation provides the insight to successfully position, price and promote your pharmaceutical, medical device or clinical service in leading healthcare market segments.
This presentation is from www.healthcaremedicalpharmaceuticaldirectory.com, no subscription is required. Please visit us to see more presentations about the latest marketing trends in the healthcare industry.
John Baresky Healthcare Marketing Leader, Pharmaceutical Marketing, Digital Marketing Strategy, Content Marketing Strategy, Market Access Strategy, Healthcare RPA Software Marketing Strategy
www.healthcaremedicalpharmaceuticaldirectory.com
John G. Baresky
https://www.linkedin.com/in/johngbaresky
#baresky
This document discusses factors related to switching medications from prescription to over-the-counter status. It begins by defining Rx-to-OTC switching as transferring FDA-approved prescription medications to non-prescription, over-the-counter status. The document then covers stakeholders impacted by switching, the switching process and principles, factors contributing to successful switches, considerations for switches, and strategies for building brand equity during and after a switch from prescription to over-the-counter status.
The document discusses the pharmaceutical market in Kenya, noting that the market size was $499.3 million in 2019 with an annual growth rate of 11.8%, driven mainly by increased government healthcare spending and improved health awareness, and that cardiovascular drugs, diabetes drugs, and anti-infectives make up approximately 78% of the prescription drug market. It also provides a SWOT analysis of the pharmaceutical industry in Kenya, regulatory information, details on drug wholesalers and distributors, and a proposed project plan and milestones for partnering with distributors.
Analysis of what patient services proposed by pharma companies should be. This document explains: 1. why patient centricity is essential? - 2. how to craft a patient-centric strategy? - 3. How to implement patient-centric initiatives?
Jungle Bar is a new protein bar infused with crickets that provides sustained energy and nutrition. It is reaching the final stages of its Kickstarter campaign to raise $15,000 for full development and launch. This public relations plan aims to raise awareness of Jungle Bar's health benefits and unique use of insects as a protein source. Key strategies include partnering with fitness centers and athletes to distribute samples, conducting street sampling events in New York City, and leveraging social and traditional media influencers to generate buzz around Jungle Bar's launch. The goal is to help Jungle Bar exceed its Kickstarter goal and introduce more people to the nutritional advantages of entomophagy.
The document provides an overview of the UK food and drink market in January 2009. It notes that while economic conditions are difficult, opportunities still exist for Swiss food producers to explore the UK market. The report summarizes that the UK market is substantial, with over £70 billion spent on food at home and £79 billion on foodservice annually. It also outlines several key issues currently affecting the UK market, such as the economic downturn, social trends like smaller household sizes, and commercial factors like the need for high food manufacturing standards.
Kraft Foods operates in 150 countries and analyzes its macroenvironment including demographic, economic, natural, technological, political, and cultural forces. Demographically, Kraft aims to target concentrated consumer groups. Economically, Kraft faces high bargaining power from both suppliers and buyers, low threat of new entrants, high rivalry among competitors, and medium threat from substitutes. Technologically, Kraft invests in R&D and modern equipment. For its market and customers, Kraft segments into health/wellness, quick meals, snacking, and premium categories and focuses on developing brand loyalty through innovation for its snack, beverage, cheese, convenient meal, and grocery products.
This document provides a situation analysis for a biotech company, Biocon, as it considers launching a new drug called BIOMab to treat head and neck cancer. It analyzes Biocon's capabilities, the market potential, competitors, and alternatives for launching BIOMab. The recommendations are to launch BIOMab immediately after approval to gain a first mover advantage, price it lower than competitors, target top oncologists directly, and promote it through continued medical education for doctors.
Making Key Decisions in New Product Planning When “Perfect” Information is No...Anthony Russell
Presentation given at New Product Planning Summit 2021.
Learning Objectives:
* Review the types of decisions typically made in New Product Planning
* Discuss the nature of information available to support decision-making in New Product Planning
* Review the impact and context of decision-making in New Product Planning
* Review potential approaches to assist in New Product Planning decision-making
Access to customers is necessary for healthcare marketing and sales initiatives to succeed. Pharmaceutical and medical device manufacturers can optimally position, price and promote their products through strategic assessment of healthcare market segments!
www.healthcaremedicalpharmaceuticaldirectory.com
John G. Baresky
https://www.linkedin.com/in/johngbaresky
John Baresky Healthcare Marketing Leader, Pharmaceutical Marketing, Digital Marketing Strategy, Content Marketing Strategy, Market Access Strategy, Healthcare RPA Software Marketing Strategy
Annalysed Case study of Virgin mobiles HARVARD UNIVERSITY CASEBSCEC
Virgin Mobile plans to target the youth market of 14-24 year olds in the US wireless industry. It considers three pricing options: 1) cloning industry prices; 2) pricing below competitors; 3) implementing a radically new plan. The analysis recommends option 3 with optimal pricing. The plan would involve shortening or eliminating contracts, offering prepaid service, increasing handset subsidies, and eliminating hidden fees and off-peak hours. This radical approach aims to attract price-sensitive youth customers by simplifying pricing and increasing transparency.
10 step marketing plan for generic pharmacy yang zhaoyang zhao
This document outlines a 10 step marketing plan for Generics Pharmacy. It identifies the primary target market as people in the Philippines who need medicine but want to pay a lower price. It analyzes competitors like Mercury Drug and positioning, noting Generics Pharmacy offers lower prices and additional services. Market size estimates vary from 6.67 to 13.1 billion pesos based on different data sources. The marketing mix involves promotional activities, distribution of 880 stores nationwide, and a winning strategy of affordable generic drugs and extra services.
This document outlines a business plan for an online pharmacy called SmartMedic. It introduces the three group members and describes the problems their service aims to address like traffic, time constraints, and access to authentic medicines. It then provides details on their vision, mission, products and services offered, target audiences, how it works, infrastructure, marketing and financial plans. The key aspects are providing prescription medicines, supplements and devices online with convenient home delivery, pharmacist review, and reminders to improve medication compliance.
MedNet is a health website that provides free, evidence-based medical information to consumers and generates profits through advertising. Windham Pharmaceuticals, an advertiser, is considering shifting its ad dollars to Marvel, a competing website. Heather Yates, MedNet's VP of business development, needs to convince Mahria Baker, Windham's CMO, to continue advertising on MedNet. Potential strategies include focusing content on new areas, increasing social media presence, and targeting ads towards common conditions many users research online.
This document provides information about the "Market Access, Pricing and Reimbursement 2016 Europe" conference, including details about its location, dates, sponsors, exhibitors, featured speakers and topics. Some of the key points mentioned are that the conference will take place from June 9-10, 2016 in London and will provide a platform for stakeholders in the pharmaceutical industry to discuss challenges and opportunities in areas like market access strategies, pricing and reimbursement trends, emerging markets, and use of real-world evidence. The document also lists over 20 industry experts who will be speaking, along with their titles and companies.
This is book review on 'MARKETING WARFARE', a Marketing Bestseller by Al Ries and Jack Trout the duo authors of book 'Positioning'. This book explains how 'Marketing is also a war played on the battlefield of 'Customer's minds'.
Kenya has a population of 48.5 million people and a pharmaceutical market worth over $423 million in 2018 that is expected to grow 11.8% annually. The market is dominated by cardiovascular, diabetes, and anti-infective drugs which account for 78% of sales. Opportunities exist to supply the growing demand due to universal healthcare initiatives, a rising middle class, and reliance on imports to meet the country's pharmaceutical needs which local manufacturers can only fulfill 30% of. Registration with the Pharmacy and Poisons Board takes 12 months and requires a dossier and plant inspection.
This document provides an overview and presentation on Walmart, including:
- A history of the company from 1945 to present.
- Details on its divisions, stocks, leadership, and mission/vision statements.
- Analyses of external opportunities/threats and internal strengths/weaknesses using various frameworks.
- Financial data and ratios comparing Walmart to competitors.
- Strategies employed including questions at the end for discussion.
Brand Differentiation in the Pharmaceutical Industry: Interview with: Robert Finkel, Principal & Chief Creative Officer, Kane & Finkel Healthcare Communications, a sponsor company at the marcus evans PharmaBrand Summit 2012, on differentiating brands in the highly restricted pharmaceuticals industry.
The document discusses Canada's orphan drug regulatory framework and opportunities to improve access to rare disease drugs across Canada. It advocates for a life-cycle approach and managed access schemes where drugs are approved with evidence collection requirements. Traditional health technology assessment limits orphan drug access by rejecting drugs that are not cost-effective based on small clinical trials. The document recommends performance-based managed access programs with national guidelines and risk-sharing between provinces, patients, and companies to improve access while collecting long-term evidence on benefits, harms, and costs.
The document discusses repurposing drugs to treat rare diseases through immediate clinical trials. It provides 6 case studies as examples. Case study 1 discusses a collaboration between government, academia, and non-profits to identify new drugs for chronic lymphocytic leukemia. Case study 2 discusses crowdfunding efforts to fund a clinical trial for a rare genetic disease. The document advocates for connecting stakeholders through an online platform called CureAccelerator and explores social finance models like social impact bonds to fund repurposing research.
The document discusses the pharmaceutical market in Kenya, noting that the market size was $499.3 million in 2019 with an annual growth rate of 11.8%, driven mainly by increased government healthcare spending and improved health awareness, and that cardiovascular drugs, diabetes drugs, and anti-infectives make up approximately 78% of the prescription drug market. It also provides a SWOT analysis of the pharmaceutical industry in Kenya, regulatory information, details on drug wholesalers and distributors, and a proposed project plan and milestones for partnering with distributors.
Analysis of what patient services proposed by pharma companies should be. This document explains: 1. why patient centricity is essential? - 2. how to craft a patient-centric strategy? - 3. How to implement patient-centric initiatives?
Jungle Bar is a new protein bar infused with crickets that provides sustained energy and nutrition. It is reaching the final stages of its Kickstarter campaign to raise $15,000 for full development and launch. This public relations plan aims to raise awareness of Jungle Bar's health benefits and unique use of insects as a protein source. Key strategies include partnering with fitness centers and athletes to distribute samples, conducting street sampling events in New York City, and leveraging social and traditional media influencers to generate buzz around Jungle Bar's launch. The goal is to help Jungle Bar exceed its Kickstarter goal and introduce more people to the nutritional advantages of entomophagy.
The document provides an overview of the UK food and drink market in January 2009. It notes that while economic conditions are difficult, opportunities still exist for Swiss food producers to explore the UK market. The report summarizes that the UK market is substantial, with over £70 billion spent on food at home and £79 billion on foodservice annually. It also outlines several key issues currently affecting the UK market, such as the economic downturn, social trends like smaller household sizes, and commercial factors like the need for high food manufacturing standards.
Kraft Foods operates in 150 countries and analyzes its macroenvironment including demographic, economic, natural, technological, political, and cultural forces. Demographically, Kraft aims to target concentrated consumer groups. Economically, Kraft faces high bargaining power from both suppliers and buyers, low threat of new entrants, high rivalry among competitors, and medium threat from substitutes. Technologically, Kraft invests in R&D and modern equipment. For its market and customers, Kraft segments into health/wellness, quick meals, snacking, and premium categories and focuses on developing brand loyalty through innovation for its snack, beverage, cheese, convenient meal, and grocery products.
This document provides a situation analysis for a biotech company, Biocon, as it considers launching a new drug called BIOMab to treat head and neck cancer. It analyzes Biocon's capabilities, the market potential, competitors, and alternatives for launching BIOMab. The recommendations are to launch BIOMab immediately after approval to gain a first mover advantage, price it lower than competitors, target top oncologists directly, and promote it through continued medical education for doctors.
Making Key Decisions in New Product Planning When “Perfect” Information is No...Anthony Russell
Presentation given at New Product Planning Summit 2021.
Learning Objectives:
* Review the types of decisions typically made in New Product Planning
* Discuss the nature of information available to support decision-making in New Product Planning
* Review the impact and context of decision-making in New Product Planning
* Review potential approaches to assist in New Product Planning decision-making
Access to customers is necessary for healthcare marketing and sales initiatives to succeed. Pharmaceutical and medical device manufacturers can optimally position, price and promote their products through strategic assessment of healthcare market segments!
www.healthcaremedicalpharmaceuticaldirectory.com
John G. Baresky
https://www.linkedin.com/in/johngbaresky
John Baresky Healthcare Marketing Leader, Pharmaceutical Marketing, Digital Marketing Strategy, Content Marketing Strategy, Market Access Strategy, Healthcare RPA Software Marketing Strategy
Annalysed Case study of Virgin mobiles HARVARD UNIVERSITY CASEBSCEC
Virgin Mobile plans to target the youth market of 14-24 year olds in the US wireless industry. It considers three pricing options: 1) cloning industry prices; 2) pricing below competitors; 3) implementing a radically new plan. The analysis recommends option 3 with optimal pricing. The plan would involve shortening or eliminating contracts, offering prepaid service, increasing handset subsidies, and eliminating hidden fees and off-peak hours. This radical approach aims to attract price-sensitive youth customers by simplifying pricing and increasing transparency.
10 step marketing plan for generic pharmacy yang zhaoyang zhao
This document outlines a 10 step marketing plan for Generics Pharmacy. It identifies the primary target market as people in the Philippines who need medicine but want to pay a lower price. It analyzes competitors like Mercury Drug and positioning, noting Generics Pharmacy offers lower prices and additional services. Market size estimates vary from 6.67 to 13.1 billion pesos based on different data sources. The marketing mix involves promotional activities, distribution of 880 stores nationwide, and a winning strategy of affordable generic drugs and extra services.
This document outlines a business plan for an online pharmacy called SmartMedic. It introduces the three group members and describes the problems their service aims to address like traffic, time constraints, and access to authentic medicines. It then provides details on their vision, mission, products and services offered, target audiences, how it works, infrastructure, marketing and financial plans. The key aspects are providing prescription medicines, supplements and devices online with convenient home delivery, pharmacist review, and reminders to improve medication compliance.
MedNet is a health website that provides free, evidence-based medical information to consumers and generates profits through advertising. Windham Pharmaceuticals, an advertiser, is considering shifting its ad dollars to Marvel, a competing website. Heather Yates, MedNet's VP of business development, needs to convince Mahria Baker, Windham's CMO, to continue advertising on MedNet. Potential strategies include focusing content on new areas, increasing social media presence, and targeting ads towards common conditions many users research online.
This document provides information about the "Market Access, Pricing and Reimbursement 2016 Europe" conference, including details about its location, dates, sponsors, exhibitors, featured speakers and topics. Some of the key points mentioned are that the conference will take place from June 9-10, 2016 in London and will provide a platform for stakeholders in the pharmaceutical industry to discuss challenges and opportunities in areas like market access strategies, pricing and reimbursement trends, emerging markets, and use of real-world evidence. The document also lists over 20 industry experts who will be speaking, along with their titles and companies.
This is book review on 'MARKETING WARFARE', a Marketing Bestseller by Al Ries and Jack Trout the duo authors of book 'Positioning'. This book explains how 'Marketing is also a war played on the battlefield of 'Customer's minds'.
Kenya has a population of 48.5 million people and a pharmaceutical market worth over $423 million in 2018 that is expected to grow 11.8% annually. The market is dominated by cardiovascular, diabetes, and anti-infective drugs which account for 78% of sales. Opportunities exist to supply the growing demand due to universal healthcare initiatives, a rising middle class, and reliance on imports to meet the country's pharmaceutical needs which local manufacturers can only fulfill 30% of. Registration with the Pharmacy and Poisons Board takes 12 months and requires a dossier and plant inspection.
This document provides an overview and presentation on Walmart, including:
- A history of the company from 1945 to present.
- Details on its divisions, stocks, leadership, and mission/vision statements.
- Analyses of external opportunities/threats and internal strengths/weaknesses using various frameworks.
- Financial data and ratios comparing Walmart to competitors.
- Strategies employed including questions at the end for discussion.
Brand Differentiation in the Pharmaceutical Industry: Interview with: Robert Finkel, Principal & Chief Creative Officer, Kane & Finkel Healthcare Communications, a sponsor company at the marcus evans PharmaBrand Summit 2012, on differentiating brands in the highly restricted pharmaceuticals industry.
The document discusses Canada's orphan drug regulatory framework and opportunities to improve access to rare disease drugs across Canada. It advocates for a life-cycle approach and managed access schemes where drugs are approved with evidence collection requirements. Traditional health technology assessment limits orphan drug access by rejecting drugs that are not cost-effective based on small clinical trials. The document recommends performance-based managed access programs with national guidelines and risk-sharing between provinces, patients, and companies to improve access while collecting long-term evidence on benefits, harms, and costs.
The document discusses repurposing drugs to treat rare diseases through immediate clinical trials. It provides 6 case studies as examples. Case study 1 discusses a collaboration between government, academia, and non-profits to identify new drugs for chronic lymphocytic leukemia. Case study 2 discusses crowdfunding efforts to fund a clinical trial for a rare genetic disease. The document advocates for connecting stakeholders through an online platform called CureAccelerator and explores social finance models like social impact bonds to fund repurposing research.
1. The document discusses opportunities for new therapies in the treatment of posterior segment disorders such as dry age-related macular degeneration (AMD), diabetic macular edema (DME), and others.
2. It finds that dry AMD represents a significant market opportunity as the first drug to successfully target and prevent progression of geographic atrophy would have a major impact, given the large patient population and lack of current treatment options.
3. Key considerations for clinical development include using change in best corrected visual acuity or rate of geographic atrophy progression as the primary endpoint, enrolling patients with intermediate disease severity for at least 2 years, and demonstrating at least a 3-line difference in visual acuity or 20% reduction in
Personalised Medicine in the EU— Evolving Landscape and New HTA ConsiderationsOffice of Health Economics
The document discusses precision medicine and health technology assessment (HTA) of complementary diagnostics in Europe. It notes that precision medicine is moving from single biomarker tests to complex multi-parameter disease management, but markets have struggled to adopt even simple biomarkers. A new paper published by Epemed identifies additional elements of value for complementary diagnostics beyond traditional HTA considerations like life years gained and cost savings. These include reducing uncertainty, value of hope, and option value of future treatments. The paper recommends changing evidentiary requirements for HTA to consider broader clinical utility and value-based pricing approaches that account for all elements of value.
Drug pricing strategies to balance patient access and the funding of innovati...Noura Aljohani
The document discusses strategies for balancing patient access to drugs with funding pharmaceutical innovation. It notes that developing a new drug takes over 10 years and $2.6 billion on average. Spending on prescription drugs makes up only 10% of total healthcare spending in the US. Cross-country drug price comparisons are misleading because pricing systems differ between countries. Alternative pricing schemes like outcomes-based agreements can help address uncertainties around drug effectiveness and outcomes. Key actions to facilitate value-based pricing in Saudi Arabia include updating regulations, improving data collection, building trust between stakeholders, and establishing standardized outcome measures.
Personalised Medicine in the EU— Evolving Landscape and New HTA ConsiderationsOffice of Health Economics
The document discusses personalised medicine and new considerations for health technology assessment (HTA) of complementary diagnostics. It provides context on precision medicine's evolution from single biomarkers to complex disease management. While markets have struggled to adopt simple biomarkers, HTA models are not well suited to emerging multi-marker tests. The white paper aims to identify HTA challenges, define diagnostic value elements beyond outcomes like expanded elements of value, and recommend approaches like considering a more comprehensive view of clinical utility in evidentiary requirements.
Health Economic and Reimbursement Implications for Emerging Pharmaceutical/ B...MaRS Discovery District
This document discusses health economics and reimbursement implications for emerging pharmaceutical and biotechnology companies. It outlines the roles of the federal and provincial governments in regulating drug prices and approving drug coverage in Canada. It emphasizes the importance of demonstrating a drug's value and return on investment to payers through strong clinical evidence, health economic analyses, and addressing payer priorities. Adopting early life-cycle strategies in these areas can help companies achieve faster market access and maximize a product's potential.
Current Approaches in European Drug related Health Care Policy: Relative Effe...Johan Strömquist
Key note speech held by Prof Bengt Jönsson from Stockholm School of Economics and Chairman of the NDA HTA Advisory Board, at the ZonMw Congres Goed Gebruik Geneesmiddelen, 31st January 2013, on the topic of dealing with decision making under uncertainty for the reimbursement of medicines
Five Steps to Find your 'Beyond the Pill' Strategyexecutiveinsight
A short window of opportunity exists for pharmaceutical companies to establish indispensable beyond the pill services, which may even help them 'own' particular disease areas.
Adapting Clinical Trials During a Global Pandemic: Lessons LearnedClinosolIndia
The COVID-19 pandemic has had a significant impact on clinical trials worldwide, requiring rapid adaptations to ensure patient safety, data integrity, and the continuity of research efforts. Several key lessons have been learned during this challenging time:
Flexibility and Adaptability: The pandemic highlighted the importance of flexibility in clinical trial design and operations. Researchers and regulatory bodies had to quickly adapt protocols to accommodate remote visits, decentralized approaches, and virtual assessments. Being able to modify protocols and implement alternative strategies allowed trials to continue while minimizing disruptions.
Remote Monitoring and Data Collection: Remote monitoring and data collection became crucial during the pandemic to ensure patient safety and collect data without in-person visits. Technologies such as wearable devices, telemedicine platforms, and electronic patient-reported outcomes (ePROs) played a significant role in enabling remote data collection and reducing the need for site visits.
Patient-Centric Approaches: The pandemic emphasized the importance of considering patients' needs and preferences. Remote visits, home healthcare services, and decentralized trial models were implemented to reduce the burden on patients and ensure their safety. Patient engagement and education became even more critical to maintain participation and retention in trials.
Regulatory Flexibility: Regulatory agencies recognized the need for flexibility during the pandemic and implemented measures to expedite trial approvals and amendments. They provided guidance on remote monitoring, virtual visits, and other alternative approaches, allowing researchers to adapt quickly while ensuring patient safety and data integrity.
This document discusses the need for patient-centered clinical trials due to rising complexity, costs and failure rates of traditional trials. It notes delays in enrollment are a major issue, inflating costs and timelines. Protocols have become more complex and burdensome, reducing adherence and retention. The future requires improving recruitment methods, incorporating patient needs, and placing data generation in patients' hands through technologies like social media and ePRO tools. Patient-centered approaches may help address these challenges and better support drug development.
IntelGenX Investor Presentation March 30 2017 ItelGenx
The presentation provides an overview of IntelGenx Corp, an innovative drug delivery company. It discusses IntelGenx's product pipeline including oral thin film versions of migraine, erectile dysfunction, and schizophrenia drugs. It also highlights a repurposed montelukast film for mild cognitive impairment currently in clinical trials. The presentation outlines IntelGenx's business strategy, partnership with Chemo, new manufacturing facility, and management team. It concludes that IntelGenx has a solid platform for growth due to its significant market potential and ability to build strategic partnerships.
This investor presentation provides an overview of IntelGenx Corp., an innovative drug delivery solutions company. It discusses IntelGenx's pipeline of oral thin film products, including products for migraines, erectile dysfunction, schizophrenia/bipolar disorder, and mild cognitive impairment. The presentation highlights IntelGenx's strategic partnerships, new manufacturing facility, strengthened management team, and recent financial performance. It concludes that IntelGenx has established a solid platform for growth by leveraging its oral thin film technology and implementing a product sourcing strategy to identify high-value opportunities.
This investor presentation provides an overview of IntelGenx Corp., an innovative drug delivery solutions company. It discusses IntelGenx's product pipeline including oral thin film versions of migraine, erectile dysfunction, and schizophrenia/bipolar drugs. The presentation highlights IntelGenx's strategic partnerships, new manufacturing facility, strengthened management team, and financial performance over recent years. It positions IntelGenx for continued growth by leveraging its drug delivery platform and oral thin film technology.
Presentation - New Business Models for Antibiotics: Where Are We Now? 16 Marc...Office of Health Economics
Speaking at the Superbugs & Superdrugs conference in London on 16 March 2016, OHE’s Jorge Mestre-Ferrandiz delivered a presentation on financial and collaborative incentives to accelerate clinical success for antibiotics.
Jorge discussed the economic challenges around antibiotics, and whether there is a need for a new business model. He reviewed of the impact of previous incentives, explaining what has worked in the past, and discussed possible new business models.
2004 Na Advate Finav 4 Intertoo Patrice Jan.19, 2004 (2)pmitsos
This document summarizes market research findings from studies on patient experiences and preferences related to hemophilia A treatment. Key points include:
- Patients primarily learn about treatments from doctors, support groups, and online research. Safety is the top concern.
- Conversions to ADVATE were mostly from Recombinate users.
- Opportunities exist to build ongoing relationships using CRM strategies and leverage high awareness of "The Baxter Factor" program.
- Challenges include optimizing outreach and targeting different patient segments like early adopters.
The document discusses the importance of early clinical recruitment planning for drug development programs. It notes that delays in recruitment can significantly increase costs and impact revenue opportunities due to later market entry. Early planning allows consideration of factors like disease characteristics, enrollment population size, competition, and protocol challenges that influence feasibility. Comprehensive recruitment programs costing 1-12% of delay costs can help avoid delays and ensure timely trial completion and drug approval.
Jan 31, 2018 How to Ensure Patient-Centred Pharmacare is Cost-Effective Healthcare A Consultation on Patented Medicine Prices Review Board & Biologic Medicines
The Role of clinical Research in Pharmaceuticals Industry
Walzer Case Study Launching And Selling A Pharmaceutical Compound With The Payer In Mind Market Access World 2012 Out
1. Case Study:
Launching and Selling
a Pharmaceutical Compound
with the Payer in Mind
Dr. Stefan Walzer
General Manager
AiM Assessment in Medicine GmbH
Tel.: +49 7621 705 105 20
stefan.walzer@assessment-in-medicine.de
2. The ultimate goal for a new compound
• The ultimate goal is Commercial Success
• Commercial success is defined by revenue
generation
Revenue = Sales * price
• Payers could influence the success of a new
compound on each side of the equation
• Sales: Caps, volume agreements, paybacks, etc.
• Price: Discount, Cost share agreement, etc.
2
3. Payer perspective critical for
commercial success
• Payers dictate global pharmaceutical pricing and
market access today.
• While there are critical costs and resource trade-
offs to consider, companies should focus on the
payer perspective throughout the drug
development and commercialization processes.
• Those that build the payer perspective into phase
III drug trials and ensure the availability of
supportive evidence for all key claims will create
a strong payer value case.
3
Source: Schonveld, Think like a payer, 2011
4. What happens if payers decide to not
reimburse a new drug?
• Implications for the pharmaceutical
company:
• No revenue generation
• No Return on Investment
• Potential lay-offs
• Implications for the patients
• No new (more efficacious) drug available
• Potential negative impact on Quality of Life
• No new future innovations which might be based on a
new compound
4
5. General market access flow combined
with key 7 payer questions
1 Why do patients need this?
Determine Funding Path or Benefit
Coverage
What am I currently paying for treating this
2 disease?
Evaluate Product
Clinical Value Economic Value How is your drug better than the
3 alternatives in my specific setting?
How much is your drug and why is it worth
4 the cost?
Determine Reimbursement Rate
Can I afford it and what part of my budget
5
will I use to fund it?
Negotiate Price & Contract
6 What are the consequences of not funding?
What patients should get it and how can
Manage Utilization 7 use be limited to appropriate patients?
5
6. When could a company influence a
positive payer decision?
• Between phase I and II program
• Early pricing & reimbursement evaluation
• Investment decisions using early modelling
• Before start of phase III program
• Payer consultation (e.g. NICE UK, GBA Germany, …)
• Joint regulatory and payer consultations
• Design of the study including the payer requirements:
– Endpoints
– Comparator
– Sample size & study power
– Subgroups / biomarker
– Minimum effect size
– Potential bias
– …
6
7. When could a company influence a
positive payer decision?
• After the availability of the phase III data
• Availability of data (final vs interim data)
• Payer consultation (e.g. NICE UK, GBA Germany, …)
• Payer story aligned with regulatory submissions
• Final pricing decision
• Health Economic data including cost-effectiveness
• Strategic Publication Planning
– Primary efficacy article
– Secondary articles
– Health Economics
7
8. Case study: Sunitinib in Renal Cell
Carcinoma
• Renal Cell Carcinoma from a payer‘s
perspective:
• Relatively low incidence / prevalence
• Few ‚old-school‘ treatments
• High clinical trial failure rate
• Low budget impact
• Oncology: Key endpoints are Overall Survival (OS) and
Progression Free Survival (PFS)
8
9. Case study: Sunitinib in Renal Cell
Carcinoma
• Early development phase:
• Dosing studies
• Potential price anchors:
– ‚Old-school‘ RCC treatments
– Innovative oncology treatments in other indications
» Erlotinib
» Bevacizumab
» Cetuximab
» Trastuzumab
» Imatinib
» Rituximab
»…
9
10. Case study: Sunitinib in Renal Cell
Carcinoma
• Preparation of the market: Awareness of
disease burden
• Epidemiological review
• Economic review
10
11. Case study: Sunitinib in Renal Cell
Carcinoma
– Start with the „worst“
patients: 2L RCC
– No comparator in trials
– Phase II trials as basis
– As efficacy results were so
astonishing Pfizer decided to
request a marketing
authorization and
reimbursement
11
12. Case study: Sunitinib in Renal Cell
Carcinoma
• However, the feedback by payers was different
(examples)
• France: ASMR III, conditional market access (before
Mediator scandal!)
• Germany: Full market access (no AMNOG at that time!)
• Italy: Long negotiations, cost-share agreement
• UK: No NICE recommendation for 2L
12
13. Case study: Sunitinib in Renal Cell
Carcinoma
• Cost-Effectiveness in 2L: Various publications
13
14. Case study: Sunitinib in Renal Cell
Carcinoma
• Break-through data in 1L
• Confirming the strong signals in 2L in front of clinical
and payer audience
• Beneficial QoL outcomes
14
15. Case study: Sunitinib in Renal Cell
Carcinoma
• Indirect Comparison and Cost-
Effectiveness in 1L
• NICE confirming cost-
effectiveness
• ASMR II in France
• Market access and fast uptake in
most countries around the world
15
16. Conclusions
• Payers dictate global pharmaceutical pricing and
market access today.
• In order to have a successful market access story the
payer perspective would need to be included as early
as possible, the latest for the information of the
phase III design
• In the case study Pfizer planned especially for a
market access in 1st line and developed an optimized
strategy for it
16
17. Thank you
Dr. Stefan Walzer
General Manager
AiM Assessment in Medicine GmbH
Tel.: +49 7621 705 105 20
stefan.walzer@assessment-in-medicine.de